Device Trial Radar · NCT06661057
Avation Electric Stimulation System for Spinal Cord Injury Neurogenic Bladder
Last checked: Nov 20, 2026Latest source record: Mar 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 1, 2024
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- The University of Texas Health Science Center, HoustonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mission Connect
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess and optimize the Avation electric stimulation system output and electromyography (EMG) processing to stimulate the tibial nerve in people with chronic Spinal Cord Injury (SCI) who have foot muscle atrophy and edema, both of which may affect proper device operations, to evaluate the safety, feasibility, and effectiveness of Avation Electric Stimulation System for bladder neuromodulation in people with SCI and identify barriers to implementation of the existing Avation Electric Stimulation System to help with developing it towards a new indication for routine care of SCI NB.
Conditions
- Neurogenic Bladder
Interventions
Vivally system stimulationDevice
During the first month, participants will do the stimulation at different time points: 1) supine while in bed, 2) seated in the morning, 3) sitting in the afternoon, and 4) sitting in the evening. Participants will measure the circumference of their ankle prior to each use. Participants will use the System for an additional 2 months with the preferred stimulation parameters based on the study team's recommendations from the first month of use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Consistency and Reliability of Stimulation Output as assessed by the percentage of sessions where the desired stimulation intensity is achieved (based on EMG waveform consistency) and time of day (morning, afternoon, evening)Time frame: Daily during the 4-week optimization period
- EMG Waveform Quality as assessed by the number of successful EMG detections per session versus unsuccessful onesTime frame: Daily during the 4-week optimization period
- Safety as assessed by the Pain score reported on the participant diaryTime frame: Continuous, daily monitoring throughout the 12-week study
10 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.